Adverse events in relation to GLP-1R agonists for the treatment of obesity are mainly gastrointestinal side effects, including nausea, diarrhoea, vomiting and constipation, which is consistent with observations in type 2 diabetes, and rates of discontinuation due to adverse events are generally higher with GLP-1R agonists treatment compared with placebo [26, 30,31,32,33,34,35,36,37,38,39]
Patients and clinicians alike are weighing the proven benefits of semaglutide against potential risks like abdominal pain, bile flow problems, or even pancreatitis
10.1111/dom.12591 64 NelsonM.BhandariN.WenerJ
( )
According to altRx, the program is available only to: Individuals who are at least 18 years of age Individuals located in the United States in a state or territory where the services are available Individuals who agree to the platform's Terms of Use, Telehealth Informed Consent, HIPAA Consent, and other published consent forms State availability is described in the brand source materials as limited, with the current state list available from altRx customer service